All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Case Report Open Access

Osimertinib Induced Interstitial Lung Disease A Case Report and Management with Literature Review


Interstitial Lung Disease (ILD) is an uncommon side effect of osimertinib, an oral Epidermal Growth Factor Receptor tyrosine kinase inhibitor (EGFR-TKI) approved for front line therapy in stage IV and adjuvant usage in stage II -III resected adenocarcinoma of the lung. We present a case of Osimertinib induced ILD in a 77 year old man with metastatic adenocarcinoma of the lung who tolerated Osimertinib rechallenge well and continued to take it for almost a year. This case study emphasizes the importance of careful Osimertinib rechallenge in a subset of patients.

Nishith Vaddeboina*, Namratha Sai Reddy, Nirni SS

To read the full article Download Full Article | Visit Full Article